
Colgate-Palmolive Company (NYSE:CL) is brushing up its future with a bold 2030 plan, even as it takes on up to $300M in restructuring charges.
The move comes as the oral care giant topped second-quarter expectations, reporting stronger-than-expected earnings and steady sales growth.